In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 15, No. 701 ( 2023-06-21)
Abstract:
Excessive Ca 2+ /calmodulin-dependent protein kinase II (CaMKII) activity has been associated with a number of cardiovascular diseases, including arrhythmias, but no CaMKII inhibitors have been approved for clinical use because of low efficacy and concerns regarding potential side effects on cognition. Here, Reyes Gaido and colleagues generated a fluorescent reporter of CaMKII activity to screen FDA-approved compounds. They identified JAK1/2 inhibitor ruxolitinib as a potent CaMKII inhibitor and demonstrated that pretreatment with this compound could effectively reduce arrythmias in vitro and in multiple mouse models without negative impacts on learning and memory. These results suggest that ruxolitinib could potentially be further developed as a treatment for certain arrhythmogenic conditions. —Allison Williams
Type of Medium:
Online Resource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.abq7839
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2023